Does the media refer more to KRYS or RVMD?

In the previous week, Revolution Medicines had 6 more articles in the media than Krystal Biotech. MarketBeat recorded 22 mentions for Revolution Medicines and 16 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.88 beat Revolution Medicines' score of 0.29 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 9 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, KRYS or NTRA?

Krystal Biotech has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 25.22 $204.83M $7.98 41.55 Natera $2.31B 19.77 -$208.16M -$1.36 N/A

Is KRYS or NTRA more profitable?

Krystal Biotech has a net margin of 54.82% compared to Natera's net margin of -7.11%. Krystal Biotech's return on equity of 19.34% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% Natera -7.11% -11.82% -8.19%

Does the media prefer KRYS or NTRA?

In the previous week, Natera had 20 more articles in the media than Krystal Biotech. MarketBeat recorded 36 mentions for Natera and 16 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.88 beat Natera's score of 0.58 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 15 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher earnings & valuation, BIIB or KRYS?

Biogen has higher revenue and earnings than Krystal Biotech. Biogen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $10.03B 3.05 $1.29B $5.65 36.66 Krystal Biotech $389.13M 25.22 $204.83M $7.98 41.55

Is BIIB or KRYS more profitable?

Krystal Biotech has a net margin of 54.82% compared to Biogen's net margin of 8.32%. Krystal Biotech's return on equity of 19.34% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Krystal Biotech 54.82% 19.34% 17.65%

Does the media prefer BIIB or KRYS?

In the previous week, Krystal Biotech had 2 more articles in the media than Biogen. MarketBeat recorded 16 mentions for Krystal Biotech and 14 mentions for Biogen. Krystal Biotech's average media sentiment score of 0.88 beat Biogen's score of 0.80 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 6 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KRYS or ALNY?

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Krystal Biotech. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 16 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.88 beat Alnylam Pharmaceuticals' score of 0.04 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ROIV or KRYS?

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 3,115.68 -$299.77M -$0.53 N/A Krystal Biotech $389.13M 25.22 $204.83M $7.98 41.55

Does the media prefer ROIV or KRYS?

In the previous week, Krystal Biotech had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 16 mentions for Krystal Biotech and 14 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.90 beat Krystal Biotech's score of 0.88 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Krystal Biotech (KRYS) Competitors

$331.59 +5.14 (+1.57%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$333.25 +1.66 (+0.50%)

As of 04:17 AM Eastern

Compare

KRYS vs. RVMD, NTRA, BIIB, ALNY, and ROIV

Should you buy Krystal Biotech stock or one of its competitors? Krystal Biotech's main competitors and comparable companies include Revolution Medicines (RVMD), Natera (NTRA), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Krystal Biotech compare to Revolution Medicines?

Krystal Biotech (NASDAQ:KRYS) and Revolution Medicines (NASDAQ:RVMD) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Revolution Medicines had 6 more articles in the media than Krystal Biotech. MarketBeat recorded 22 mentions for Revolution Medicines and 16 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.88 beat Revolution Medicines' score of 0.29 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	9 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.22	$204.83M	$7.98	41.55
Revolution Medicines	$11.58M	3,830.91	-$1.13B	-$8.82	N/A

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Krystal Biotech currently has a consensus target price of $361.56, indicating a potential upside of 9.04%. Revolution Medicines has a consensus target price of $160.68, indicating a potential downside of 22.36%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91

Krystal Biotech has a net margin of 54.82% compared to Revolution Medicines' net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

Krystal Biotech beats Revolution Medicines on 11 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Natera?

Krystal Biotech (NASDAQ:KRYS) and Natera (NASDAQ:NTRA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Krystal Biotech has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.22	$204.83M	$7.98	41.55
Natera	$2.31B	19.77	-$208.16M	-$1.36	N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has a net margin of 54.82% compared to Natera's net margin of -7.11%. Krystal Biotech's return on equity of 19.34% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Natera	-7.11%	-11.82%	-8.19%

In the previous week, Natera had 20 more articles in the media than Krystal Biotech. MarketBeat recorded 36 mentions for Natera and 16 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.88 beat Natera's score of 0.58 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	15 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

Krystal Biotech presently has a consensus target price of $361.56, indicating a potential upside of 9.04%. Natera has a consensus target price of $301.90, indicating a potential downside of 5.17%. Given Krystal Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Krystal Biotech is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77

Summary

Krystal Biotech beats Natera on 11 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Biogen?

Biogen (NASDAQ:BIIB) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Biogen presently has a consensus price target of $224.61, suggesting a potential upside of 8.44%. Krystal Biotech has a consensus price target of $361.56, suggesting a potential upside of 9.04%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92

87.9% of Biogen shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Krystal Biotech has a net margin of 54.82% compared to Biogen's net margin of 8.32%. Krystal Biotech's return on equity of 19.34% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Krystal Biotech	54.82%	19.34%	17.65%

In the previous week, Krystal Biotech had 2 more articles in the media than Biogen. MarketBeat recorded 16 mentions for Krystal Biotech and 14 mentions for Biogen. Krystal Biotech's average media sentiment score of 0.88 beat Biogen's score of 0.80 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	6 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has higher revenue and earnings than Krystal Biotech. Biogen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.05	$1.29B	$5.65	36.66
Krystal Biotech	$389.13M	25.22	$204.83M	$7.98	41.55

Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Summary

Krystal Biotech beats Biogen on 12 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Krystal Biotech (NASDAQ:KRYS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Krystal Biotech. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 16 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.88 beat Alnylam Pharmaceuticals' score of 0.04 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has higher revenue and earnings than Krystal Biotech. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.22	$204.83M	$7.98	41.55
Alnylam Pharmaceuticals	$4.80B	6.04	$313.75M	$5.38	40.33

Krystal Biotech currently has a consensus price target of $361.56, suggesting a potential upside of 9.04%. Alnylam Pharmaceuticals has a consensus price target of $396.72, suggesting a potential upside of 82.84%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

Summary

Krystal Biotech and Alnylam Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Krystal Biotech has a net margin of 54.82% compared to Roivant Sciences' net margin of -3,534.96%. Krystal Biotech's return on equity of 19.34% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Krystal Biotech	54.82%	19.34%	17.65%

In the previous week, Krystal Biotech had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 16 mentions for Krystal Biotech and 14 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.90 beat Krystal Biotech's score of 0.88 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Roivant Sciences currently has a consensus price target of $35.14, indicating a potential downside of 1.80%. Krystal Biotech has a consensus price target of $361.56, indicating a potential upside of 9.04%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,115.68	-$299.77M	-$0.53	N/A
Krystal Biotech	$389.13M	25.22	$204.83M	$7.98	41.55

Summary

Krystal Biotech beats Roivant Sciences on 12 of the 15 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export

Metric	Krystal Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.66B	$3.70B	$7.01B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.07%
P/E Ratio	41.55	9.09	269.20	24.72
Price / Sales	25.22	1,265.42	592.83	98.22
Price / Cash	44.78	44.95	28.89	37.42
Price / Book	7.88	18.00	11.39	6.42
Net Income	$204.83M	-$13.25M	$3.45B	$347.03M
7 Day Performance	2.10%	3.10%	1.92%	0.69%
1 Month Performance	-9.35%	-1.68%	-0.57%	-0.90%
1 Year Performance	141.09%	61.75%	75.49%	21.87%

Krystal Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	3.5236 of 5 stars	$331.59 +1.6%	$361.56 +9.0%	+139.1%	$9.66B	$389.13M	41.55	210
RVMD Revolution Medicines	1.5572 of 5 stars	$182.45 -2.7%	$144.67 -20.7%	+491.3%	$39.87B	$11.58M	N/A	250	Earnings Report Analyst Forecast
NTRA Natera	2.9105 of 5 stars	$270.36 +1.0%	$267.83 -0.9%	+109.5%	$38.35B	$2.50B	N/A	6,140	Earnings Report Analyst Forecast
BIIB Biogen	3.8869 of 5 stars	$201.82 -0.6%	$223.89 +10.9%	+58.5%	$29.99B	$9.89B	35.72	7,500
ALNY Alnylam Pharmaceuticals	4.7165 of 5 stars	$220.33 +7.2%	$402.67 +82.8%	-50.6%	$27.50B	$3.71B	40.95	2,770

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. RVMD, NTRA, BIIB, ALNY, and ROIV

How does Krystal Biotech compare to Revolution Medicines?

Summary

How does Krystal Biotech compare to Natera?

Summary

How does Krystal Biotech compare to Biogen?

Summary

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. RVMD, NTRA, BIIB, ALNY, and ROIV

How does Krystal Biotech compare to Revolution Medicines?

Does the media refer more to KRYS or RVMD?

Which has more volatility and risk, KRYS or RVMD?

Which has preferable earnings & valuation, KRYS or RVMD?

Do institutionals and insiders have more ownership in KRYS or RVMD?

Do analysts prefer KRYS or RVMD?

Is KRYS or RVMD more profitable?

Summary

How does Krystal Biotech compare to Natera?

Which has stronger earnings & valuation, KRYS or NTRA?

Do institutionals & insiders hold more shares of KRYS or NTRA?

Is KRYS or NTRA more profitable?

Does the media prefer KRYS or NTRA?

Which has more volatility & risk, KRYS or NTRA?

Do analysts rate KRYS or NTRA?

Summary

How does Krystal Biotech compare to Biogen?

Do analysts rate BIIB or KRYS?

Do insiders and institutionals have more ownership in BIIB or KRYS?

Is BIIB or KRYS more profitable?

Does the media prefer BIIB or KRYS?

Which has higher earnings & valuation, BIIB or KRYS?

Which has more volatility and risk, BIIB or KRYS?

Summary

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Do insiders & institutionals hold more shares of KRYS or ALNY?

Which has more volatility and risk, KRYS or ALNY?

Is KRYS or ALNY more profitable?

Does the media prefer KRYS or ALNY?

Which has preferable valuation & earnings, KRYS or ALNY?

Do analysts prefer KRYS or ALNY?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Is ROIV or KRYS more profitable?

Does the media prefer ROIV or KRYS?

Which has more volatility & risk, ROIV or KRYS?

Do analysts prefer ROIV or KRYS?

Do insiders and institutionals have more ownership in ROIV or KRYS?

Which has stronger valuation & earnings, ROIV or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools